北美血尿治疗市场预测至 2028 年 - COVID-19 影响和治疗(药物、疗法等)、适应症(尿路感染、肾结石、尿道炎、血癌、膀胱结石、前列腺癌、膀胱炎、创伤)的区域分析、剧烈运动、多囊肾、子宫内膜异位症和月经)、类型(肉眼血尿、镜下血尿、特发性血尿和慢跑者血尿)、最终用户(医院、诊所和门诊手术中心等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 158    |    Report Code: TIPRE00026252    |    Category: Life Sciences

North America Hematuria Treatment Market

市场介绍

血尿是一种在尿液中发现血液的疾病。一般来说,尿液中不含红细胞,因此可能会导致严重的问题,还可能导致肾结石、尿路感染和其他遗传性疾病。

此外,血尿的患病率很高预计相关迹象将在预测期内促进市场增长。然而,相关适应症的未确诊病例限制了北美血尿治疗市场的增长。

大流行为肾病市场的参与者提供了重要的增长机会。这种可能性是由于受冠状病毒影响的患者数量不断增加。例如,根据美国肾脏病学会的报告,为了应对 COVID-19,入住重症监护病房 (ICU) 的一半冠状病毒阳性患者出现肾衰竭,需要某种形式的透析。报告指出,ICU 中约有 10% 至 50% 的患者出现肾衰竭,近 17% 的患者需要紧急透析,46% 的患者出现某种形式的急性肾损伤 (AKI)。在整个北美地区,美国登记的受冠状病毒影响的患者人数最多。因此,越来越多的患者面临更高的急性肾损伤(AKI)风险,包括肾小管损伤伴感染性休克、微炎症、凝血增加以及可能的肾脏直接感染。因此,预计将增加对肾脏疾病管理产品的需求,从而导致未来市场的增长。

市场概况和动态

北美血尿治疗市场预计将从2021年的3.516亿美元增至2028年的4.197亿美元;预计 2021 年至 2028 年复合年增长率为 2.6%。医疗设备和诊断程序的技术发展带来了治疗血尿相关适应症的多种选择,例如肾结石、膀胱结石和尿路感染。先进治疗技术的使用有望改善患者护理。例如,近年来,机器人技术在治疗尿石症手术中的应用越来越受欢迎。目前,Intuitive Surgical Inc. 的 Vinci 手术系统广泛用于治疗尿石症的手术。同样,各国对肾结石的腔内泌尿外科干预措施的采用也显着增加。预计相关适应症的进步可能会在预测期内支持北美血尿治疗市场。

关键细分市场

从类型来看,肉眼血尿细分市场在2020年北美血尿治疗市场中占据最大份额。从治疗来看,药物细分市场在2020年北美血尿治疗市场中占据最大份额。从适应症来看,尿路感染细分市场在2020年北美血尿治疗市场中占据最大份额。从最终用户来看,医院细分市场占据2020年北美血尿治疗市场最大份额。

主要来源和上市公司

准备本北美血尿治疗市场报告时参考的一些主要一手和二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司包括阿斯利康、百时美施贵宝公司、F. HOFFMANN-LA ROCHE LTD.、葛兰素史克公司、杨森制药、默沙东制药公司和默沙东制药公司。 Co., Inc.、Novartis AG、Pfizer Inc.、Sun Pharmaceutical Industries Ltd 和 Boehringer Ingelheim International GmbH。

购买报告的理由

  • 了解北美血尿治疗市场格局并确定细分市场可能保证丰厚的回报
  • 了解不断变化的市场格局并在竞争中保持领先
  • 通过识别最有可能销售的细分市场,有效规划北美血尿治疗市场的并购和合作交易
  • 通过敏锐而全面的分析,做出明智的业务决策各个细分市场的市场表现
  • 获得2021年-2028年基于各个细分市场的北美血尿治疗市场的市场收入预测

北美血尿治疗市场细分

作者

治疗

  • 药物
  • 疗法
  • 其他

按适应症 span>

  • 尿路感染
  • 肾结石
  • 尿道炎
  • 血癌
  • 膀胱结石
  • 前列腺癌
  • 膀胱炎
  • 外伤
  • 剧烈运动
  • 多囊肾
  • 子宫内膜异位症
  • 月经
  • 子宫内膜异位症
  • 月经
  • span>

类型

  • 肉眼血尿
  • 显微镜下血尿
  • 特发性血尿
  • 慢跑者血尿

最终用户

  • 医院
  • 诊所
  • 门诊手术中心 (ASC)
  • 其他

按国家/地区

    < li>北美
  • 美国
  • 加拿大
  • 墨西哥

提及的公司

  • 阿斯利康
  • 百时美施贵宝公司
  • F. HOFFMANN-LA ROCHE LTD.
  • 葛兰素史克公司
  • 杨森制药
  • 默克公司有限公司
  • 诺华公司
  • 辉瑞公司
  • < span>太阳制药工业有限公司
  • 勃林格殷格翰国际有限公司


North America Hematuria Treatment Strategic Insights

Strategic insights for North America Hematuria Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-hematuria-treatment-market-strategic-framework.webp
Get more information on this report

North America Hematuria Treatment Report Scope

Report Attribute Details
Market size in 2021 US$ 351.6 Million
Market Size by 2028 US$ 419.7 Million
Global CAGR (2021 - 2028) 2.6%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 治疗
  • 药物
  • 疗法
By 适应症
  • 泌尿道感染
  • 肾结石
  • 尿道炎
  • 血癌
  • 膀胱结石
  • 前列腺癌
  • 膀胱炎
  • 创伤
  • 剧烈运动
  • 多囊肾病
  • 子宫内膜异位症
  • 月经
By 类型
  • 肉眼血尿
  • 显微镜下血尿
  • 特发性血尿
  • 慢跑者血尿
By 最终用户
  • 医院
  • 诊所
  • 门诊手术中心
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Get more information on this report

    North America Hematuria Treatment Regional Insights

    The regional scope of North America Hematuria Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-hematuria-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - North America Hematuria Treatment Market

    1. AstraZeneca
    2. Bristol-Myers Squibb Company
    3. F. HOFFMANN-LA ROCHE LTD.
    4. GlaxoSmithKline plc.
    5. Janssen Pharmaceuticals
    6. Merck & Co., Inc.
    7. Novartis AG
    8. Pfizer Inc.
    9. Sun Pharmaceutical Industries Ltd
    10. Boehringer Ingelheim International GmbH
    Frequently Asked Questions
    How big is the North America Hematuria Treatment Market?

    The North America Hematuria Treatment Market is valued at US$ 351.6 Million in 2021, it is projected to reach US$ 419.7 Million by 2028.

    What is the CAGR for North America Hematuria Treatment Market by (2021 - 2028)?

    As per our report North America Hematuria Treatment Market, the market size is valued at US$ 351.6 Million in 2021, projecting it to reach US$ 419.7 Million by 2028. This translates to a CAGR of approximately 2.6% during the forecast period.

    What segments are covered in this report?

    The North America Hematuria Treatment Market report typically cover these key segments-

  • 治疗 (药物, 疗法)
  • 适应症 (泌尿道感染, 肾结石, 尿道炎, 血癌, 膀胱结石, 前列腺癌, 膀胱炎, 创伤, 剧烈运动, 多囊肾病, 子宫内膜异位症, 月经)
  • 类型 (肉眼血尿, 显微镜下血尿, 特发性血尿, 慢跑者血尿)
  • What is the historic period, base year, and forecast period taken for North America Hematuria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Hematuria Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in North America Hematuria Treatment Market?

    The North America Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Who should buy this report?

    The North America Hematuria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.